Alto Neuroscience, Inc. (ANRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

LOS ANGELES, CA / ACCESSWIRE / December 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto ...

announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The ...

JonesTrading analyst Justin Walsh initiated coverage with a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target of $18.00. The company’s shares closed ...

Alto Neuroscience, Inc. has a 12 month low of $3.61 and a 12 month high of $24.00. The stock has a 50 day moving average of $6.49 and a 200-day moving average of $10.07.

Vigil Neuroscience, Inc. has a 12-month low of $1.99 and a 12-month high of $6.06. The stock has a fifty day moving average of $3.24 and a 200-day moving average of $3.56.